InvestorsHub Logo
Followers 3158
Posts 963907
Boards Moderated 195
Alias Born 09/04/2000

Re: BEIJING BILL post# 518142

Friday, 09/18/2020 3:48:40 PM

Friday, September 18, 2020 3:48:40 PM

Post# of 621651
WOW $ABUS READ

RE;
JUST IN: $ABUS Arbutus Announces AB-729 90 mg Single-Dose Week 12 Data in Chronic Hepatitis B Subjects Demonstrating Significant and Continuous Reductions in HBsAg

Mean HBsAg reduction of 1.23 log 10 IU/mL at week 12 with a favorable safety and tolerability profile WARMINSTER, Pa., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developin...

Find out more ABUS - Arbutus Announces AB-729 90 mg Single-Dose Week 12 Data in Chronic Hepatitis B Subjects Demonstrating Significant and Continuous Reductions in HBsAg
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.